Cargando…

Introduction: challenging established dogma

Detalles Bibliográficos
Autor principal:	Santen, Richard J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Section Introduction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2230524/ http://dx.doi.org/10.1186/bcr1814

Ejemplares similares

Introduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6
por: Wishart, Gordon C, et al.
Publicado: (2009)

Session 6 introduction
por: Robertson, John FR, et al.
Publicado: (2010)

Introduction to sessions on Personalising treatment
por: Dowsett, Mitch, et al.
Publicado: (2007)

Introduction to clinical research sessions
por: Ingle, James N
Publicado: (2007)

Introduction to session on undue and disproportionate influences
por: Ingle, James N, et al.
Publicado: (2010)

Risk factors. Introduction to Session 1
por: Howell, Anthony, et al.
Publicado: (2009)

Introduction to sessions on 'Predicting personal risk for breast cancer'
por: Dowsett, Mitch
Publicado: (2008)

The potential of new technologies/approaches. Introduction to Sessions 3 and 4
por: Dowsett, Mitch
Publicado: (2009)

Introduction to sessions on 'Optimizing the implementation of future treatments – time to abandon traditional methods'
por: Verrill, Mark
Publicado: (2008)

Introduction: are current drug development programmes realising the full potential of new agents?
por: Johnston, Stephen RD, et al.
Publicado: (2010)

Introduction to sessions on 'What can surgeons do for us (and we for them): radiology, pathology, molecular biology and local therapy'
por: Dixon, J Michael, et al.
Publicado: (2008)

Debate: tailored targeted therapy for all - a realistic and worthwhile objective? Introduction to Session 2
por: Smith, Ian E
Publicado: (2009)

Who would have thought it! Influence on outcome of radiotherapy, Ki67 and stroma. Introduction to Session 5
por: Rodger, Alan
Publicado: (2009)

Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8
por: Johnston, Stephen RD
Publicado: (2009)

Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to?'
por: Ingle, James N
Publicado: (2008)

Introduction to the sessions on 'Debate: Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors'
por: Fallowfield, Lesley, et al.
Publicado: (2008)

Introduction
por: Tice, Jeffrey A., et al.
Publicado: (2007)

The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction
por: Eyal, Nir
Publicado: (2017)

Introduction to The Special Issue: Novel Molecular Pathways and Therapeutic Challenges in Neurodegenerative Diseases
por: Kosagisharaf, Jagannatha Rao, et al.
Publicado: (2023)

Introduction from the Editors
por: Kim, Harold, et al.
Publicado: (2018)

Introduction
por: Cook, Harold J
Publicado: (2009)

Introduction
por: Eagleton, Matthew J., et al.
Publicado: (2020)

Introduction
por: Polman, Chris H., et al.
Publicado: (2007)

Introduction
por: Snyder, Michael
Publicado: (2008)

Introduction
por: Udelsman, Robert
Publicado: (2008)

Introduction
Publicado: (2009)

Introduction
por: Collinge, John, et al.
Publicado: (2008)

Introduction
por: Boulet, Louis-Philippe
Publicado: (2010)

Introduction
por: Menko, Fred H.
Publicado: (2011)

Introduction
por: Godefroy, Samuel B.
Publicado: (2011)

Introduction
por: Mackenzie, Campbell
Publicado: (2005)

Introduction
por: Nutton, Vivian
Publicado: (2008)

Introduction
por: Gatzemeier, U
Publicado: (2003)

Introduction
por: Lypson, Monica L., et al.
Publicado: (2010)

Introduction
Publicado: (2011)

Introduction
Publicado: (2009)

Introduction
Publicado: (2010)

Introduction
Publicado: (2012)

Introduction
por: Rizzo, Riccardo, et al.
Publicado: (2013)

Introduction
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5li80fe5q1ik58aitsk6cl6gdu